Chronic allograft nephropathy - a clinical syndrome: Early detection and the potential role of proliferation signal inhibitors

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 769-777

  Campistol, Josep M ^a   Boletis, Ioannis N ^b   Dantal, Jacques ^c   de Fijter, Johan W ^d   Hertig, Alexandre ^e   Neumayer, Hans H ^f   Øyen, Ole ^g   Pascual, Julio ^h   Pohanka, Erich ⁱ   Ruiz, Juan C ^j   Scolari, Maria P ^k   Stefoni, Sergio ^k   Serón, Daniel ^l   Sparacino, Vito ^m   Arns, Wolfgang ⁿ   Chapman, Jeremy R ^o  

^a UNIVERSITY OF BARCELONA   (Spain)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c HÔTEL DIEU   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HÔPITAL TENON   (France)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m Renal Unit   (Italy)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

Chronic allograft nephropathy; Everolimus; Glomerular filtration rate; Proliferation signal inhibitors mammalian target of rapamycin inhibitors; Renal function; Renal transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; CALCINEURIN;

ACUTE GRAFT REJECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EARLY INTERVENTION; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; METABOLIC DISORDER; NEPHROTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TREATMENT WITHDRAWAL; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHRONIC DISEASE; DELAYED GRAFT FUNCTION; DRUG EFFECTS; KIDNEY TRANSPLANTATION; METABOLISM; PROGNOSIS; SIGNAL TRANSDUCTION; SYNDROME;

CALCINEURIN; CELL PROLIFERATION; CHRONIC DISEASE; DELAYED GRAFT FUNCTION; EARLY DIAGNOSIS; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROGNOSIS; SIGNAL TRANSDUCTION; SIROLIMUS; SYNDROME; TRANSPLANTATION, HOMOLOGOUS; CALCINEURIN INHIBITORS;

EID: 71149092881     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01057.x     Document Type: Review

References (80)

1. Macdonald S, Chang S, Excell L. ANZDATA Registry Report 2006 2006, Adelaide, Australia, Australia and New Zealand Dialysis and Transplantation Registry
2. Meier Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378.
3. Excell L, Chadban S, MacDonald S, Excell L, Macdonald S. Transplantation in ANZDATA Registry Report 2004. http://www.anzdata.org.au/v1/index.html, In, eds, Adelaide, Australia, Australia and New Zealand Dialysis and Transplantation Registry,
4. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346:580.
5. Sijpkens YWJ, Doxiadis N, de Fijter JW. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999, 56:1920.
6. Nankivell BJ, Borrows RJ, Fung CL-S. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326.
7. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 kidney transplant study group. Transplantation 1998, 66:1736.
8. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015.
9. Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999, 55:713.
10. Solez K, Colvin RB, Racusen LC. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (" CAN" ). Am J Transplant 2007, 7:518.
11. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006, 6:2006.
12. Serón D, Moreso F, Bover J. Early protocol renal allograft biopsies and graft outcome. Kidney Int 1997, 51:310.
13. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006, 81:643.
14. Levey AS, Bosch JP, Breyer Lewis J. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461.
15. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473.
16. Raju DL, Grover VK, Shoker A. Limitations of glomerular filtration rate equations in the renal transplant patient. Clin Transplant 2005, 19:259.
17. Gera M, Slezak JM, Rule AD. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant 2007, 7:880.
18. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31.
19. Nankivell BJ, Gruenewald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995, 59:1683.
20. Marqués GG, Goenaga PE, Royo FJL, Escolá JM, Fernández NG, Unanua AP. Evolution of the renal function is a better predictor of long-term survival than serum creatinine. Transplant Proc 2005, 37:3701.
21. Sijpkens YWJ, Zwinderman AH, Mallat MJK. Intercept and slope analysis of risk factors in chronic renal allograft nephropathy. Graft 2002, 5:108.
22. Watson CJE, Firth J, Williams PF. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005, 5:2496.
23. Moreso F, Ibernon M, Gomà M. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006, 6:747.
24. Chapman JR. Longitudinal analysis of chronic allograft nephropathy: clinicopathologic correlations. Kidney Int 2005, 68(Suppl 99):108.
25. Lietz K, Lewandowski Z, Lao M, Paczek L, Gaciong Z. Pretransplant and early posttransplant predictors of chronic allograft nephropathy in cadaveric kidney allograft - a single-center analysis of 1112 cases. Transpl Int 2004, 17:78.
26. Meyers CM, Kirk AD. Workshop on late renal allograft dysfunction. Am J Transplant 2005, 5:1600.
27. Morath C, Lange U, Klein A, Zeier M, Arns W. High responder rate after calcineurin-inhibitor withdrawal and introduction of sirolimus therapy in patients with deteriorating renal function. Transplantation 2006, 82(Suppl 3):498. Abstract 1280
28. Arias M, Fernandez-Fresnedo G, Rodrigo E. Non-immunologic intervention in chronic allograft nephropathy. Kidney Int Suppl 2005, 99:S118.
29. Arns W, Citterio F, Campistol JM. 'Old-for-old'- new strategies for renal transplantation. Nephrol Dial Transplant 2007, 22:336.
30. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33:278.
31. Djamali A, Sadowski EA, Samaniego-Picota M. Noninvasive assessment of early kidney allograft dysfunction by blood oxygen level-dependent magnetic resonance imaging. Transplantation 2006, 82:621.
32. Scholbach T, Girelli E, Scholbach J. Tissue pulsatility index: a new parameter to evaluate renal transplant perfusion. Transplantation 2006, 81:751.
33. Mas V, Maluf D, Archer K. Establishing the molecular pathways involved in chronic allograft nephropathy for testing new non-invasive diagnostic markers. Transplantation 2007, 83:448.
34. Cheng OH, Kampen RL, Hoffmann SC, Kirk AD, Mannon RB. Look into the crystal ball: using gene expression arrays to predict chronic allograft nephropathy. Transplantation 2006, 82(Suppl 3):239. Abstract 511
35. Serón D, Arns W, Chapman JR. Chronic allograft nephropathy - clinical guidance for early detection and early intervention strategies. Nephrol Dial Transplant 2008, 23:2467.
36. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A - short-term gain, long-term pain?. Nephrol Dial Transplant 2006, 21:2060.
37. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557.
38. Pascual J. Concentration-controlled everolimus (Certican®): combination with reduced dose calcineurin inhibitors. Transplantation 2005, 79(Suppl 3):S76.
39. Lutz J, Zou H, Liu S, Antus B, Heemann U. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003, 76:508.
40. Vitko S, Tedesco H, Eris J. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004, 4:626.
41. Kumar MSA, Heifets M, Fyfe B. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005, 80:807.
42. Sumethkul V, Changsirikulchai S, Lothuvachai T, Chalermsanyakorn P. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy. Transplantation 2006, 82(Suppl 3):3470. Abstract 1134
43. Changsirikulchai S, Chalermsanyakorn P, Watanapokasin R, Sumethkul V. Cyclosporine reduction and sirolimus or mycophenolate mofetil addition attenuate the progressive decline of graft function and stabilize TGF-β1 levels in chronic allograft nephropathy. Am J Transplant 2006, 6(Suppl 2):507.
44. Flechner SM, Kurian SM, Solez K. De novo kidney transplantation without the use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004, 4:1776.
45. Oberbauer R, Segoloni G, Campistol JM. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005, 18:22.
46. Mota A, Arias M, Taskinen EI. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004, 4:953.
47. Ruiz JC, Campistol JM, Grinyó JM. Early cyclosporine A withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004, 78:1312.
48. Ruiz JC, Campistol JM, Mota A. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc 2003, 35:1669.
49. Stallone G, Di Paolo S, Schena A. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003, 75:998.
50. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systemic review of randomized trials. Am J Transplant 2005, 5:1748.
51. Fischereder M, Graeb C, Kruger B. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 2006, 38:1295.
52. Stallone G, Infante B, Schena A. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005, 16:3755.
53. Wali RK, Cooper M, Foster C. Early tacrolimus withdrawal and rescue therapy with sirolimus in high-risk renal transplant recipients with moderate to severe chronic allograft nephropathy. Transplantation 2006, 82(Suppl 3):1572. Abstract 1715
54. Ibañez J, Monteverde M, Diaz M, Goldberg J, Turconi A. Sirolimus effect on chronic allograft dysfunction in pediatric renal recipients. Am J Transplant 2006, 6(Suppl 2):571. Abstract 1504.5
55. Diekmann F, Budde K, Oppenheimer F. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004, 4:1869.
56. Gonzalez Molina M, Serón D, Garcia del Moral R. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004, 77:215.
57. Dudley C, Pohanka E, Riad H. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the " Creeping Creatinine" study. Transplantation 2005, 79:466.
58. Pascual M, Williams WW, Cosimi AB, Delmonico FL, Farrell ML, Tolkoff-Rubin N. Chronic renal allograft dysfunction: a role for mycophenolate mofetil?. Transplantation 2000, 69:1749.
59. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001, 7:473.
60. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006, 21:562.
61. Schena FP, Vitko S, Wali R. Efficacy and Safety of Conversion from Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients: 18-Month results from a Randomized, Open-Label Comparative Trial 2006, Poster presented at the World Transplant Congress, Boston, MA, USA, July 22-27, Abstract 1026
62. Rapamune® Summary of Product Characteristics 2007, Maidenhead, Wyeth Europa Ltd
63. Rapamune® (Sirolimus) Oral Solution and Tablets. Prescribing Information 2007, Philadelphia, PA, Wyeth Pharmaceuticals, Inc
64. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican®) in renal transplantation: a review of clinical trial data, current usage and future directions. Transplant Rev 2006, 20:1.
65. Chan L, Cooper M, Leventhal J, Munir L. Excellent renal function at 6 months in de novo kidney transplant recipients treated with everolimus, basiliximab and reduced tacrolimus exposure. Transplantation 2006, 82(Suppl 3):299. Abstract 689
66. Kovarik JM, Figueiredo J, Rouilly M, O'Bannon LF, Rordorf C. Differential of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002, 42:95.
67. Pohanka E. Conversion to everolimus in maintenance patients - current clinical strategies. Nephrol Dial Transplant 2006, 21(Suppl 3):24.
68. Lebranchu Y, Etienne I, Touchard E. Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients receiving Mycophenolate Mofetil (MMF) 2007, 7(Suppl 2):160. Presented at the Am J Transplant, Abstract 53
69. Budde K, Glander P, Schuhmann R. Conversion from cyclosporine to everolimus leads to better renal function and to profound changes in everolimus and mycophenolate metabolism. Transplantation 2006, 82(Suppl 3):999. Abstract 2867
70. Holdaas H, Pfeffer P, Bentdal T, Midtvedt K. Conversion from Cyclosporine to Everolimus at Week 7 after Renal Transplantation is Safe and Improves Renal Function 2007, 7(Suppl 2). Presented at Am J Transplant, Abstract 1709
71. Ekberg H, Tedesco-Silva H, Demirbas A. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med 2007, 357:2562.
72. Campistol JM, Oberbauer R, Schena F. Am J Transplant 2006, 6(Suppl 2):412.
73. Kovarik JM, Curtis JJ, Hricik DE, Pescovitz MD, Scantlebury V, Vasquez A. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006, 38:3456.
74. Arns W, Glander P, Schuhmann R. Am J Transplant 2006, 6(Suppl 2):488.
75. Bumbea V, Kamar N, Ribes D. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005, 20:2517.
76. Ruiz JC, Campistol JM, Sánchez-Fructuoso A. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006, 21:3252.
77. Stracke S, Mayer JM, Henne-Bruns D, Keller F. Elevated serum levels of vascular endothelial growth factor (VEGF) and proteinuria in renal allograft recipients treated with mTOR inhibitors. Am J Transplant 2006, 6(Suppl 2):299. Abstract 688
78. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003, 14:3217.
79. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000, 4(Suppl 1):S97.
80. Amer H, Fidler ME, Myslak M. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007, 7:2748.